Natural and Synthetic LDL-Based Imaging Probes for the Detection of Atherosclerotic Plaques
Open Access
- 4 February 2025
- journal article
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 8 (2) , 578-591
Abstract
Low-density lipoprotein (LDL) is the primary natural carrier of lipids in the bloodstream and plays a central role in the development of atherosclerosis. By leveraging LDL's natural tendency to accumulate at sites of plaque formation, LDL can be employed as a carrier to selectively deliver the imaging probes to efficiently detect atherosclerotic plaques. In our previous studies, we reported several LDL-based magnetic resonance imaging contrast agents (MRI-CAs) formed by modifying natural LDL (nLDL) or developing LDL-mimetic (synthetic LDL, sLDL) from lipid nanoparticles (LNPs) utilizing chemical reactions on the nanoparticle surface, including preliminary MRI tests. In this study, we report the in vivo biological functionality of these LDLs (both nLDL and sLDL)-based Gd(III)-based contrast agents (GBCAs) by conducting detailed in vivo studies on two types of atherosclerosis murine models, namely, apoE -/- and LDLr -/- . We provide more comprehensive MRI data accompanied by ex vivo results, including microscopic analysis of aorta segments for LDL accumulation and whole-body cryoVIZ analysis for biodistribution of the probe. We also tested in vitro cellular internalization of sLDL on two cell lines (RAW 264.7 and THP-1), which are derived from macrophages and monocytes, respectively, in order to observe sLDL uptake by macrophages, which are often present at the vulnerable types of atherosclerotic plaques. In conclusion, our current study demonstrates that modified LDLs-both nLDL and sLDL-facilitate MRI detection of atheroplaques by efficient uptake by macrophages. Taken together with the high loading capacity of Gd(III)-chelate molecules on LDL, especially sLDL, the LDL-based MRI contrast agents reported here hold significant potential for the early detection of atherosclerosis, including vulnerable ones, and should be useful for preventive diagnosis strategies.Keywords
Funding Information
- Schweizerischer Nationalfonds zur F?rderung der Wissenschaftlichen Forschung (205321_173018)
- Schweizerischer Nationalfonds zur F?rderung der Wissenschaftlichen Forschung (IZLJZ2_183660)
- American Heart Association (0930140N)
- Precursory Research for Embryonic Science and Technology
- ETH Research Grant (ETH-21_15-2)
- ETH Research Grant (ETH-36_20-2)
This publication has 47 references indexed in Scilit:
- Small rodent models of atherosclerosisBiomedicine & Pharmacotherapy, 2020
- Recent Advances in Managing Atherosclerosis via NanomedicineSmall, 2017
- The use of THP-1 cells as a model for mimicking the function and regulation of monocytes and macrophages in the vasculatureAtherosclerosis, 2012
- Scavenger receptors: Implications in atherothrombotic disordersThe International Journal of Biochemistry & Cell Biology, 2011
- Modified natural nanoparticles as contrast agents for medical imagingAdvanced Drug Delivery Reviews, 2010
- Macrophage-Specific Lipid-Based Nanoparticles Improve Cardiac Magnetic Resonance Detection and Characterization of Human AtherosclerosisJACC: Cardiovascular Imaging, 2009
- An ApoA‐I Mimetic Peptide High‐Density‐Lipoprotein‐Based MRI Contrast Agent for Atherosclerotic Plaque Composition DetectionSmall, 2008
- Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiformeJournal of Controlled Release, 2007
- Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiformeInternational Journal of Pharmaceutics, 2007
- MRI of atherosclerosisJournal of Magnetic Resonance Imaging, 2004